^
    Back
    Association details:
    Biomarker:NRAS Q61K
    Cancer:Thyroid Gland Carcinoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

    Excerpt:
    Nine patients had a BRAF V600E mutation, 5 had an NRAS mutation at codon 61 (Q→R or K), 3 had RET/PTC rearrangements....All five patients with NRAS-mutant tumors had increased iodine uptake in response to selumetinib; four had confirmed partial responses and one had stable disease after radioiodine administration
    DOI:
    10.1056/NEJMoa1209288
    Trial ID:
    NCT00970359